Efficiency of anlotinib hydrochloride as 3rd line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect.

Qiming Wang,Jianxing He,Baolan Li,Kai Li,Zhehai Wang,Yi Luo,Xiuwen Wang,Weiqiang Chen,Baohui Han,Li Zhang,Yuankai Shi,Faguang Jin,Jianhua Shi,Ying Cheng,Kejun Nan

doi:10.1200/jco.2018.36.15_suppl.e21182

Efficiency of anlotinib hydrochloride as 3rd line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect.

Qiming Wang, Jianxing He + Show 13 more

https://doi.org/10.1200/jco.2018.36.15_suppl.e21182

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2018
Citations: 1

Affiliation: Henan Cancer Hospital, First Affiliated Hospital of Guangzhou Medical University, Beijing Chest Hospital, Tianjin Medical University, Shandong Tumor Hospital, Shandong First Medical University, Hunan Cancer Hospital, Qilu Hospital of Shandong University, Lanzhou Army General Hospital, Shanghai Chest Hospital, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Jilin Province Tumor Hospital, First Affiliated Hospital of Xi'an Jiaotong University

#Advanced NSCLC Pts #3rd Line Treatment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

e21182Background: ALTER 0303 trial (NCT02388919) has demonstrated that anlotinib could significantly prolonged OS (primary point) and PFS in refractory advanced NSCLC pts as 3rd line treatment. Met...

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.